3626 results for «229»

Filter By

3626 results

TAVI and mitral interventions

17 Feb 2019 – From PCR Tokyo Valves 2019

Consult this session to discover challenging TAVI and mitral interventions, such as: bioprosthetic valve fracture, concomitant off-pump beating heart mitral repair and LAA closure, annulus rupture immediately after balloon-expandable transcatheter heart valve implantation, and more!

TAVI and mitral interventions

Excellent abstracts from Japan

17 Feb 2019 – From PCR Tokyo Valves 2019

Consult this session in English and Japanese to learn more about various TAVI studies and cases, regarding topics such as comparison between self- and balloon- expandable valve, clinical outcomes of the 20mm SAPIEN 3, single proglide vascular preclose technique, and more!

Excellent abstracts from Japan

PCR Tokyo Valves 2019 Opening Ceremony

16 Feb 2019 – From PCR Tokyo Valves 2019

Consult this session to discover the slides of PCR Tokyo Valves 2019 Opening Ceremony, a course which is expanding to become the major Asian forum in valvular interventions.

PCR Tokyo Valves 2019 Opening Ceremony

Bioresorbable scaffolds versus permanent sirolimus-eluting stents in patients with ST-segment elevation myocardial infarction: vascular healing outcomes from the MAGSTEMI trial

27 Dec 2020

The MAGSTEMI trial showed larger endothelium-independent vasodilatation with magnesium-based bioresorbable scaffolds (MgBRS) than with sirolimus-eluting stents (SES). However, restenosis was more frequent with MgBRS. The aims of this study were to compare the healing pattern between MgBRS and SES and to describe the main causes of...

Authors :

J. Gomez-Lara, L. Ortega-Paz, S. Brugaletta, J. Cuesta, S. Romaní, A. Serra, P. Salinas, B. García del Blanco, J. Goicolea, R. Hernandez-Antolín, P. Antuña, R. Romaguera, A. Regueiro, F. Rivero, Àngel Cequier, F. Alfonso, J.Antoni Gómez-Hospital, M. Sabaté
EuroIntervention: BRS versus permanent sirolimus-eluting stents in patients with STEMI: vascular healing outcomes from the MAGSTEMI trial

No go (again) for oral anticoagulation after TAVR: Results of the ADAPT-TAVR trial

04 Apr 2022

Francesco Costa analyses the results of ADAPT-TAVR, a prospective randomized trial on edoxaban vs dual antiplatelet therapy for valve thrombosis and cerebral thromboembolism after transcatheter aortic-valve replacement.

Francesco Costa

Author

Francesco Costa
A Randomized ADAPT-TAVR Trial: Edoxaban Vs DAPT For Valve Thrombosis and Cerebral Thromboembolism After TAVR

TRILUMINATE pivotal: A landmark randomized clinical trial of transcatheter tricuspid valve edge-to-edge repair for tricuspid regurgitation

04 Mar 2023

Jonathan Curio and Alex Sticchi provide their take on this clinical trial which was presented by Paul Sorajja at the American College of Cardiology Scientific Session (ACC.23/WCC).

Alessandro Sticchi

Author

Alessandro Sticchi
Jonathan Curio

Author

Jonathan Curio
Live from ACC.23/WCC: TRILUMINATE pivotal
Didn’t find what you were looking for?